JP2010540653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540653A5 JP2010540653A5 JP2010528107A JP2010528107A JP2010540653A5 JP 2010540653 A5 JP2010540653 A5 JP 2010540653A5 JP 2010528107 A JP2010528107 A JP 2010528107A JP 2010528107 A JP2010528107 A JP 2010528107A JP 2010540653 A5 JP2010540653 A5 JP 2010540653A5
- Authority
- JP
- Japan
- Prior art keywords
- nlrr
- egfr
- cancer
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97689207P | 2007-10-02 | 2007-10-02 | |
| US60/976,892 | 2007-10-02 | ||
| PCT/US2008/078474 WO2009046123A2 (en) | 2007-10-02 | 2008-10-01 | Nlrr-1 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540653A JP2010540653A (ja) | 2010-12-24 |
| JP2010540653A5 true JP2010540653A5 (enExample) | 2013-10-10 |
| JP5695905B2 JP5695905B2 (ja) | 2015-04-08 |
Family
ID=40526943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528107A Expired - Fee Related JP5695905B2 (ja) | 2007-10-02 | 2008-10-01 | Ｎｌｒｒ−１アンタゴニスト及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8691222B2 (enExample) |
| EP (1) | EP2207805B1 (enExample) |
| JP (1) | JP5695905B2 (enExample) |
| AU (1) | AU2008308761B2 (enExample) |
| CA (1) | CA2699601A1 (enExample) |
| ES (1) | ES2502217T3 (enExample) |
| WO (1) | WO2009046123A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2264462B1 (en) * | 2008-03-04 | 2012-11-07 | Hisamitsu Pharmaceutical Co., Inc. | Screening method for a therapeutic agent for cancer |
| WO2019222506A1 (en) * | 2018-05-16 | 2019-11-21 | Chang Gung Memorial Hospital, Linkou | Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP2111870A1 (en) * | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US7265210B2 (en) * | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
| AU2003253677A1 (en) * | 2002-06-11 | 2003-12-22 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
| WO2006130135A1 (en) * | 2005-05-31 | 2006-12-07 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| WO2007050798A2 (en) * | 2005-10-26 | 2007-05-03 | Five Prime Therapeutics, Inc. | Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer |
| US20080311107A1 (en) * | 2006-02-17 | 2008-12-18 | Genetech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
-
2008
- 2008-10-01 EP EP08835102.8A patent/EP2207805B1/en active Active
- 2008-10-01 CA CA2699601A patent/CA2699601A1/en not_active Abandoned
- 2008-10-01 JP JP2010528107A patent/JP5695905B2/ja not_active Expired - Fee Related
- 2008-10-01 ES ES08835102.8T patent/ES2502217T3/es active Active
- 2008-10-01 US US12/680,243 patent/US8691222B2/en not_active Expired - Fee Related
- 2008-10-01 WO PCT/US2008/078474 patent/WO2009046123A2/en not_active Ceased
- 2008-10-01 AU AU2008308761A patent/AU2008308761B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114206930B (zh) | 针对抗cd73抗体和变体的方法和组合物 | |
| JP7256127B2 (ja) | がんのための診断及び治療方法 | |
| ES2850428T3 (es) | Procedimientos de monitorización y tratamiento del cáncer | |
| US20090226455A1 (en) | Combination therapy with c-met and her antagonists | |
| US20160303127A1 (en) | Combination therapy with c-met and egfr antagonists | |
| CN102498129B (zh) | 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移 | |
| CN102216331A (zh) | 治疗方法 | |
| US20180282415A1 (en) | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer | |
| JP2012524083A (ja) | アジュバント癌治療 | |
| JP2022512744A (ja) | 肉腫様腎臓がんのための診断および治療方法 | |
| JP5695905B2 (ja) | Ｎｌｒｒ−１アンタゴニスト及びその使用 | |
| JP2010540653A5 (enExample) | ||
| HK1146065B (en) | Nlrr-1 antagonists and uses thereof | |
| WO2011082187A1 (en) | Methods for modulating a pdgf-aa mediated biological response | |
| RU2825390C2 (ru) | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit | |
| HK40071709B (zh) | 针对抗cd73抗体和变体的方法和组合物 | |
| HK40016679A (en) | Therapeutic and diagnostic methods for cancer | |
| AU2017202820A1 (en) | Combination therapy with c-met and HER antagonists |